Cabometyx improved progression-free survival in sufferers with superior neuroendocrine tumors originating within the gastrointestinal tract in comparison with placebo.
In contrast with placebo, Cabometyx (cabozantinib) improved progression-free survival (PFS) after development on prior remedy for extrapancreatic neuroendocrine tumors (NETs) with a main tumor arising within the gastrointestinal (GI) tract, as demonstrated in subgroup knowledge from the CABINET trial offered on the 2025 Gastrointestinal Cancers Symposium.
The VEGF-targeted agent additionally improved PFS versus placebo in sufferers with numerous scientific elements, besides in these with a main web site of a non-midgut GI tumor.
Findings from the evaluation revealed that sufferers within the extrapancreatic NET cohort with a main tumor arising within the GI tract (116 sufferers) skilled a median PFS of 8.5 months within the Cabometyx arm (70 sufferers) versus 5.6 months within the placebo arm (46 sufferers). Finest general responses within the Cabometyx and placebo arms included confirmed partial response (1% versus 0%), secure illness (69% versus 65%) and progressive illness (9% versus 26%), and sufferers had been additionally not evaluable (21% versus 9%), respectively.
“New therapeutic choices are wanted for sufferers with superior NETs,” Dr. Jonathan Strosberg, chief of the Neuroendocrine Tumor Division and Division of Gastrointestinal Oncology Analysis Program at Moffitt Most cancers Heart in Tampa, Florida, wrote in a poster presentation of the findings. “Potential profit was noticed throughout scientific elements together with grade, practical standing, [use] concurrent somatostatin analogs and prior remedy.”
Prior knowledge from CABINET confirmed that Cabometyx considerably improved PFS versus placebo in sufferers with beforehand handled, progressive superior extrapancreatic or pancreatic NETs. Confirmed goal response charges had been 5% and 19% in sufferers with extrapancreatic and pancreatic NETs, respectively.
GIossary:
Development-free survival: the time throughout and after remedy when a affected person with most cancers is alive with out the illness worsening.
Finest general response: the perfect end result seen throughout the remedy interval when it comes to how the most cancers responded to the remedy.
Goal response charge: the share of sufferers with a whole or partial response to remedy inside a time frame.
ECOG efficiency rating of 1 or 2: the affected person is ready to stroll and do mild actions however can not do strenuous actions, or they’re able to deal with themselves however unable to work.
Sufferers enrolled in CABINET had grade I to III effectively to reasonably differentiated NETs and had skilled illness development inside 12 months previous to random task following remedy with not less than one prior FDA-approved systemic remedy, not together with somatostatin analogs. They had been then assigned to the extrapancreatic NET arm or pancreatic NET arm and randomly assigned to obtain Cabometyx or placebo. The principle focus of the trial was to evaluate PFS.
Baseline Affected person Traits From the Subgroup Evaluation
The median variety of prior systemic therapies acquired, not together with somatostatin analogs, was one in each the Cabometyx and placebo arms. All sufferers had acquired somatostatin analogs beforehand, and most had acquired Afinitor (everolimus; 61% versus 54%) or Lutathera (lutetium Lu 177 dotatate; 79% versus 74%), and a few got Temodar (temozolomide)–primarily based therapies (17% versus 15%).
The median period of remedy was 5.8 months amongst sufferers handled with Cabometyx (68 sufferers) and three.7 months amongst these given placebo (45 sufferers). Moreover, 13 versus 7 sufferers remained on remedy within the respective arms. Causes for discontinuation included progressive illness, uncomfortable side effects, withdrawn consent and loss of life on examine.
Further Findings and Security
Cabometyx yielded a PFS profit versus placebo amongst all scientific issue teams examined on this subgroup evaluation other than in these with a main tumor web site of non-midgut GI. Essentially the most pronounced profit was seen in those that had not acquired prior Lutathera, had grade I illness, had an ECOG efficiency rating of 1 or 2 and who had a main tumor web site of midgut GI.
The protection profile of Cabometyx was according to beforehand reported knowledge, and on this affected person inhabitants handled with the agent (68 sufferers) versus placebo (45 sufferers), grade 3 (extreme) to 4 (life-threatening) uncomfortable side effects occurred in 60% versus 18% of sufferers. Notable grade 3 to 4 uncomfortable side effects included hypertension (19% versus 4%), diarrhea (13% versus 4%) and fatigue (10% versus 4%), respectively. Grade 5 (loss of life) toxicities that will have been associated to check remedy occurred in three sufferers handled with Cabometyx; one affected person skilled cardiac arrest, and the opposite two causes of loss of life weren’t specified.
Reference:
“Efficacy and security of cabozantinib for superior gastrointestinal (GI) neuroendocrine tumors (NET) after development on prior remedy: subgroup evaluation of the part 3 CABINET trial (Alliance A021602).” By Dr. Jonathan Strosberg, et al. Introduced at: 2025 Gastrointestinal Cancers Symposium; 2025 Jan 16-18; San Francisco, CA. Summary 666
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
